Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

about

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

Item

http://www.wikidata.org/entity/Q36278557

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Potential effect of spliceosom ...... irrespective of the MYC status

@ast

Potential effect of spliceosom ...... irrespective of the MYC status

@en

type

Item

label

Potential effect of spliceosom ...... irrespective of the MYC status

@ast

Potential effect of spliceosom ...... irrespective of the MYC status

@en

prefLabel

Potential effect of spliceosom ...... irrespective of the MYC status

@ast

Potential effect of spliceosom ...... irrespective of the MYC status

@en

P1476

Potential effect of spliceosom ...... irrespective of the MYC status

@en

P2093

Christopher J Rivard

http://www.w3.org/2001/XMLSchema#string

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Hui Yu

http://www.w3.org/2001/XMLSchema#string

Kim Ellison

http://www.w3.org/2001/XMLSchema#string

Leslie Rozeboom

http://www.w3.org/2001/XMLSchema#string

Tetsuya Mitsudomi

http://www.w3.org/2001/XMLSchema#string

P2860

A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis

MYC oncogenes and human neoplastic disease.

Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.

Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells.

Therapeutic Targeting of Myc.

An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor

The spliceosome is a therapeutic vulnerability in MYC-driven cancer.

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.

P304

e0172209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0172209

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kenichi Suda

P577

2017-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28192473

http://www.w3.org/2001/XMLSchema#string

P921

Spliceosome

P932

5305228

http://www.w3.org/2001/XMLSchema#string